» Articles » PMID: 18048389

In Vitro and in Vivo Cytotoxic Effects of PRIMA-1 on Hepatocellular Carcinoma Cells Expressing Mutant P53ser249

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2007 Dec 1
PMID 18048389
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is highly lethal due to limited curative options. In high-incidence regions, such as parts of Africa and Southeastern Asia, >50% of cases carry an AGG to AGT mutation at codon 249 of the TP53 gene, considered as a 'signature' of mutagenesis by aflatoxins. The protein product, p53ser249, may represent a therapeutic target for HCC. The small molecule p53 reactivation and induction of massive apoptosis (PRIMA)-1 has been shown to induce apoptosis in tumour cells by reactivating the transactivation capacity of some p53 mutants. In this study, we have investigated the cytotoxic effects of PRIMA-1 on HCC cells expressing p53ser249. In p53-null Hep3B cells, over-expression of p53ser249 or p53gln248 by stable transfection increased the cytotoxicity of PRIMA-1 at 50 muM. Furthermore, PRIMA-1 treatment delayed the growth of p53ser249-expressing Hep3B cells xenografted in severe combined immunodeficiency mice. However, PRIMA-1 did not restore wild-type DNA binding and transactivation activities to p53ser249 or to p53gln248 in Hep3B cells. Moreover, in PLC/PRF/5, a HCC cell line constitutively expressing p53ser249, small interfering RNA (siRNA) silencing of the mutant increased the cytotoxic effect of PRIMA-1. These apparently contradictory effects can be reconciled by proposing that p53ser249 exerts a gain-of-function effect, which favours the survival of HCC cells. Thus, both inhibition of this effect by PRIMA-1 and removal of the mutant by siRNA can lead to the decrease of survival capacity of HCC cells.

Citing Articles

PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.

Paz M, Ferretti G, Martins-Dinis M, Ferreira B, Faier-Pereira A, Barnoud T Front Mol Biosci. 2023; 10:1165132.

PMID: 37101558 PMC: 10123287. DOI: 10.3389/fmolb.2023.1165132.


The role of autophagy in cardiovascular disease: Cross-interference of signaling pathways and underlying therapeutic targets.

Jiang B, Zhou X, Yang T, Wang L, Feng L, Wang Z Front Cardiovasc Med. 2023; 10:1088575.

PMID: 37063954 PMC: 10090687. DOI: 10.3389/fcvm.2023.1088575.


Anticancer Therapeutic Strategies Targeting p53 Aggregation.

Ferretti G, Quarti J, Dos Santos G, Rangel L, Silva J Int J Mol Sci. 2022; 23(19).

PMID: 36232329 PMC: 9569952. DOI: 10.3390/ijms231911023.


Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?.

Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F Cells. 2021; 10(1).

PMID: 33430525 PMC: 7827888. DOI: 10.3390/cells10010098.


The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets.

Cui J, Shen H, Lim L Pharmaceuticals (Basel). 2020; 13(12).

PMID: 33260729 PMC: 7760785. DOI: 10.3390/ph13120432.